QN-302 is under clinical development by Qualigen Therapeutics and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase I drugs for Pancreatic Ductal Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the QN-302 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

QN-302 overview

QN-302 is under development for the treatment of solid tumors such as pancreatic ductal adenocarcinoma (PDAC), sarcomas, prostate cancer, metastatic colorectal cancer and gastrointestinal stromal tumor (GIST). It acts by targeting genomic quadruplex (G4). It is administered through intravenous route.

Qualigen Therapeutics overview

Qualigen Therapeutics (Qualigen) develops therapeutics for the treatment of cancer and infectious diseases. The company’s cancer therapeutics pipeline includes QN-247 and RAS-F. QN-247 is a (DNA) coated gold nanoparticle cancer drug candidate to target various types of cancer. QN-247 is a nanoparticle coating technology that is similar to the core nanoparticle coating technology used in blood-testing diagnostic products. QN-165 is a drug candidate for treating viral-based infectious diseases. RAS-F is a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins and preventing binding tumor growth, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device candidate for removal from circulating blood of precisely targeted tumor-produced and viral compounds. Qualigen is headquartered in Los Angeles, California, the US.

For a complete picture of QN-302’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.